# Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine

> **NCT00483717** · PHASE2 · COMPLETED · sponsor: **Egalet Ltd** · enrollment: 173 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Ketorolac tromethamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00483717
- **Lead sponsor:** Egalet Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483717, "Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00483717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*